Prevalence of adverse reactions after dengue vaccine in a young population, in Paraná
Vacuna contra el dengue y reacciones adversas
DOI:
https://doi.org/10.5433/1679-0367.2023v44n1p71Keywords:
Immunization, Vaccination, Adverse EventsAbstract
Objective: the present study’s purpose is to demonstrate the prevalence of dengue vaccine adverse events and its correlation with sociodemographic and clinical characteristics.
Material and Methodology: as a cohort study, a questionnaire and phone interviews were applied to the young adults, and data was collected from a database of local services, the Laboratory Environment Manager of Paraná, and the Dengue Vaccination Control Application. The relation between variables and the presence of vaccine reaction was made via the chi-squared and Fisher exact tests, afterwards, the binary logistic regression method was applied.
Results: from 1,815 participants, 6.5% have had some reaction, systemic or local, after receiving the vaccine dose. The most recurrent reactions identified were headaches (59.6%), followed by malaise (32.1%), fever (26.6%), myalgia (22%), local pain (14.6%), considering the last one the only reaction present in three vaccine doses. The first vaccine dose has had a greater chance of reaction comparing to the subsequent doses (p<0.0001). Being female [OR 1.701 (1.144-2.5416), p<0.009] increased the chance of vaccine reaction; however, to have an underlying disease [OR 0.001(0.000-0.002), p=0.000] was a protective factor.
Conclusion: the study demonstrated low adverse reactions in the population vaccinated with the dengue vaccine.
Downloads
References
Arragain L, Dupont-Rouzeyrol M, O'Connor O, Sigur N, Grangeon JP, Huguon E, et al. Vertical transmission of dengue virus in the peripartum period and viral kinetics in newborns and breast milk: new data. J Pediatric Infect Dis. Soc. 2017;6:324-31. doi: 10.1093/jpids/piw058
Busch MP, Sabino EC, Brambilla D, Lopes ME, Capuani L, Chowdhury D, et al. Duration of dengue viremia in blood donors and relationships between donor viremia, infection incidence and clinical case reports during a large epidemic. J Infect Dis. 2016;214:49-54. doi: 10.1093/infdis/jiw122
Capeding MR, Tran NH, Hadinegoro SR, Hj Muhammad Ismail HIH , Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014,384:1358-65. doi:10.1016/S0140-6736(14)61060-6
Centers for Disease Control and Prevention. Dengue: CDC [Internet]. 2021 [cited 2023 Jun 12]. Available from: https://www.cdc.gov/dengue/.
Dayan GH, Garbes P, Noriega F, Sadovsky ADI, Rodrigues PM, Giuberti C, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg. 2013;89:1058-65. doi: 10.4269/ajtmh.13-0304
Dengue vaccine: WHO position paper, september 2018 - recommendations. Vaccine. 2019;37(35):4848-9. doi: 10.1016/j.vaccine.2018.09.063
Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Hum. Vaccines Immunother. 2016;12:512-8. doi: 10.1080/21645515.2015.1076598
Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41:239-49. doi: 10.1007/s00281-018-0726-5
Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577-99. doi: 10.1146/annurev-cellbio-100616-060718
Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2:16055. doi: 10.1038/nrdp.2016.55
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-1206. doi: 10.1056/NEJMoa1506223
Hirve S, Newman LP, Paget J, Azziz-Baumgartner E, Fitzner J, Bhat N, et al. Influenza seasonality in the tropics and subtropics - When to vaccinate? PLoS One. 2016;11(4):e0153003. doi: 10.1371/journal.pone.0153003
Khobragade AW, Kadam DD. Efficacy of tetravalent dengue vaccine: a systematic review and meta-analysis. Indian J Community Med. 2021,46:191-4. doi: 10.4103/ijcm.IJCM_608_20
Kimberlin, David W; Barnett, Elizabeth, Lynfield Ruth, editors. Red Book 2021: report of the Committee on Infectious Diseases [Internet]. Itasca: American Academy of Pediatrics; 2021 [cited 2023 Jun 10]. Available from: http://www.reddepadressolidarios.com/img/1rps_1634118322_a.pdf.
Kraemer MUG, Reiner Jr RC, Brady OJ, Messina JP, Gilbert M, Pigott DM, Kraemer MUG, et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019;4: 854-63. doi:10.1038/s41564-019-0376-y
Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum. Vaccines Immunother. 2012;8:1259-71. doi: 10.4161/hv.21224
Nath KD, Burel JG, Shankar V, Pritchard AL, Towers M, Looke D, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:51-6. doi: 10.2147/COPD.S53590
Organização Pan-Americana da Saúde. Dengue [Internet]. 2021 [citado 2023 jun 13]. Disponível em: https://www.paho.org/pt/topicos/dengue.
Ruggierii A, Anticoli S, D’ambrosio A, Giordani L, Mora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016;52:198-204. doi: 10.4415/ANN_16_02_11
Sabino EC, Loureiro P, Lopes ME, Capuani L, McClure C, Chowdhury D, et al. Transfusion-Transmitted dengue and associated clinical symptoms during the 2012 epidemic in Brazil. J Infect Dis. 2016;213:694-702. doi: 10.1093/infdis/jiv326
Sanofi Pasteur. Dengvaxia: um guia de referência rápido para auxiliar profissionais de saúde [Internet]. 2019 [citado 2023 jun 10]. Disponível em: https://sbmt.org.br/wp-content/uploads/2019/03/PDF2.pdf.
Segerstrom SC, Hardy JK, Evans DR, Greenberg RN. Vulnerability, distress, and immune response to vaccination in older adults. Brain Behav Immun. 2012,26:747-53. doi: 10.1016/j.bbi.2011.10.009
Sociedade Brasileira de Medicina Tropical. ANVISA atualiza bula da vacina contra a dengue [Internet]. 2019 [citado 2023 jun 12]. Disponível em: https://www.sbmt.org.br/portal/material-informativo-dengvaxia/
Sociedade de Pediatria do Estado do Rio de Janeiro. Perguntas e respostas vacinação contra dengue [Internet]. Rio de Janeiro: SOPERJ; 2019 [citado 2023 jun 8]. Disponível em: http://soperj.com.br/perguntas-respostas-vacinacao-contra-dengue/.
Tully D, Griffiths CL. Dengvaxia: the world's first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021;9:25151355211015839. doi: 10.1177/25151355211015839
Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518-28. doi: 10.1038/nrmicro1690
Wiggins KB, Smith MA, Schultz-Cherry S. The nature of immune responses to influenza vaccination in high-risk populations. Viruses. 2021;13(6):1109. doi: 10.3390/v13061109
Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol. 2020;43:71-8. doi: 10.1016/j.coviro.2020.09.004
World Health Organization. Background paper on dengue vaccines: prepared by the SAGE working group on dengue vaccines and WHO secretariat [Internet]. 2016 [cited 2023 Jun 10]. Available from: http://www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf.
Zimmermann P, Curtis N. Factors That influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-18. doi: 10.1128/CMR.00084-18
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Danielle Ruiz Miyazawa Ferreira, Lucas Gabriel Capelari, Ivana Teixeira Motta, Jaqueline Dario Capobiango
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
adopts the CC-BY-NC license for its publications, the copyright being held by the author, in cases of republication we recommend that authors indicate first publication in this journal.
This license allows you to copy and redistribute the material in any medium or format, remix, transform and develop the material, as long as it is not for commercial purposes. And due credit must be given to the creator.
The opinions expressed by the authors of the articles are their sole responsibility.
The magazine reserves the right to make normative, orthographic and grammatical changes to the originals in order to maintain the cultured standard of the language and the credibility of the vehicle. However, it will respect the writing style of the authors. Changes, corrections or suggestions of a conceptual nature will be sent to the authors when necessary.
This Journal is licensed with a license Creative Commons Assignment-NonCommercial 4.0 International.